D	C27884	C177537	GDC Value Terminology	C27884	Bladder Papillary Urothelial Neoplasm of Low Malignant Potential	A papillary neoplasm of the urinary bladder in which the transitional cells form papillae.  The papillary structures exhibit minimal architectural distortion and minimal atypia.  Mitoses are infrequent.  Patients are at an increased risk of developing new papillary lesions.  Occasionally, the new lesions are urothelial carcinomas.	8130/1 | morphology || Papillary transitional cell neoplasm of low malignant potential | primary_diagnosis || Papillary urothelial neoplasm of low malignant potential | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
D	C3234	C177537	GDC Value Terminology	C3234	Mesothelioma	A usually malignant and aggressive neoplasm of the mesothelium which is often associated with exposure to asbestos.	9050/3 | morphology || Mesothelioma | relationship_primary_diagnosis || Mesothelioma, NOS | primary_diagnosis	C176985 || C177621 || C178243	morphology || primary_diagnosis || relationship_primary_diagnosis
D	C39816	C177537	GDC Value Terminology	C39816	Infiltrating Bladder Urothelial Carcinoma with Squamous Differentiation	An invasive transitional cell carcinoma of the bladder that exhibits squamous differentiation.	Urothelial carcinoma with squamous differentiation | primary_diagnosis	C177621	primary_diagnosis
D	C39818	C177537	GDC Value Terminology	C39818	Infiltrating Bladder Urothelial Carcinoma with Trophoblastic Differentiation	A variant of infiltrating bladder urothelial carcinoma. It is characterized by the presence of trophoblastic differentiation within the carcinoma.	Urothelial carcinoma with trophoblastic differentiation | primary_diagnosis	C177621	primary_diagnosis
D	C39819	C177537	GDC Value Terminology	C39819	Infiltrating Bladder Urothelial Carcinoma, Nested Variant	A variant of infiltrating bladder urothelial carcinoma. It is characterized by a nested growth pattern.	Nested urothelial carcinoma | primary_diagnosis	C177621	primary_diagnosis
D	C39820	C177537	GDC Value Terminology	C39820	Infiltrating Bladder Urothelial Carcinoma, Microcystic Variant	A variant of infiltrating bladder urothelial carcinoma. It is characterized by microcysts formation. It is also associated with intracytoplasmic mucin deposits and calcification in cyst walls.	Microcystic urothelial carcinoma | primary_diagnosis	C177621	primary_diagnosis
D	C39827	C177537	GDC Value Terminology	C39827	Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant	An invasive transitional cell carcinoma of the bladder characterized by the presence of clear cells.	Clear cell (glycogen-rich) urothelial carcinoma | primary_diagnosis	C177621	primary_diagnosis
D	C39828	C177537	GDC Value Terminology	C39828	Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant	A variant of infiltrating bladder urothelial carcinoma characterized by the presence of lipid laden tumor cells.	Lipid-rich urothelial carcinoma | primary_diagnosis	C177621	primary_diagnosis
A	C190163	C177537	GDC Value Terminology	C190163	BAI File	An index file found in the same directory as the binary alignment map (BAM) file, a compressed binary version of a sequence alignment/map (SAM) file.	BAI | data_format	C42761	data_format
A	C190164	C177537	GDC Value Terminology	C190164	BCR Biotab Format	Files that consist of aggregate clinical and biospecimen data across all cases of the given project. Biotab files are supplemental files that are available in the Genomic Data Commons (GDC) Legacy Archive as tab-delimited files on a project level basis. These may also include fields that are not available in the GDC application programming interface (API).	BCR Biotab | data_format	C42761	data_format
A	C191370	C177537	GDC Value Terminology	C191370	Renal Cell Carcinoma, Not Otherwise Specified	A renal cell carcinoma that cannot be classified into one of the established subtypes of renal cell carcinoma.	8312/3 | morphology || Renal cell carcinoma, NOS | primary_diagnosis || Renal cell carcinoma, unclassified | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
A	C191672	C177537	GDC Value Terminology	C191672	Papillary Urothelial Neoplasm of Low Malignant Potential	A papillary neoplasm of the urothelium. The papillary structures exhibit minimal architectural distortion and minimal atypia. Mitoses are infrequent. It usually occurs in the urinary bladder, but it can arise from other sites in the urinary tract. Patients are at an increased risk of developing new papillary lesions. Occasionally, the new lesions are urothelial carcinomas.	8130/1 | morphology || Papillary transitional cell neoplasm of low malignant potential | primary_diagnosis || Papillary urothelial neoplasm of low malignant potential | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
A	C191681	C177537	GDC Value Terminology	C191681	Invasive Urothelial Carcinoma with Squamous Differentiation	An invasive urothelial carcinoma that exhibits squamous differentiation.	Urothelial carcinoma with squamous differentiation | primary_diagnosis	C177621	primary_diagnosis
A	C191682	C177537	GDC Value Terminology	C191682	Invasive Urothelial Carcinoma with Trophoblastic Differentiation	An invasive urothelial carcinoma characterized by the presence of trophoblastic differentiation.	Urothelial carcinoma with trophoblastic differentiation | primary_diagnosis	C177621	primary_diagnosis
A	C191683	C177537	GDC Value Terminology	C191683	Invasive Clear Cell (Glycogen-Rich) Urothelial Carcinoma	An invasive urothelial carcinoma characterized by the presence of clear (glycogen-rich) cells.	Clear cell (glycogen-rich) urothelial carcinoma | primary_diagnosis	C177621	primary_diagnosis
A	C191684	C177537	GDC Value Terminology	C191684	Invasive Lipid-Rich Urothelial Carcinoma	Invasive urothelial carcinoma characterized by the presence of lipid laden tumor cells.	Lipid-rich urothelial carcinoma | primary_diagnosis	C177621	primary_diagnosis
A	C191685	C177537	GDC Value Terminology	C191685	Invasive Microcystic Urothelial Carcinoma	Invasive urothelial carcinoma characterized by microcysts formation.	Microcystic urothelial carcinoma | primary_diagnosis	C177621	primary_diagnosis
A	C191687	C177537	GDC Value Terminology	C191687	Invasive Nested Urothelial Carcinoma	Invasive urothelial carcinoma characterized by a nested growth pattern.	Nested urothelial carcinoma | primary_diagnosis	C177621	primary_diagnosis
A	C191737	C177537	GDC Value Terminology	C191737	Affymetrix CEL Format	A type of file that stores the results of intensity calculations of pixel values for DNA microarray image analysis. The data includes an intensity value, standard deviation of the intensity, the number of pixels used to calculate the intensity value, a flag to indicate an outlier as calculated by the algorithm, and a user defined flag indicating whether the feature should be excluded from future analysis. The file also stores the previously stated data for each feature on the probe array.	CEL | data_format	C42761	data_format
A	C191741	C177537	GDC Value Terminology	C191741	Urinary Tract	The parts of the urinary system that discharge urine. These include the renal pelvis, ureters, bladder, and urethra.	Urinary Tract | biospecimen_anatomic_site || Urinary Tract | treatment_anatomic_site	C171435 || C70729	biospecimen_anatomic_site || treatment_anatomic_site
C	C102534	C177537	GDC Value Terminology	C102534	SPOP Gene	This gene is involved in protein ubiquitination, which often leads to proteasomal degradation.	SPOP | gene_symbol || SPOP | second_gene_symbol	C171253 || C173595	second_gene_symbol || gene_symbol
C	C112177	C177537	GDC Value Terminology	C112177	Zabadinostat	A novel histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Although the exact therapeutic mechanism of action for CXD101 is not known, oral administration of this agent should inhibit the catalytic activity of HDAC, which results in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling and an altered pattern of gene expression. HDAC, a family of enzymes upregulated in many tumor types, deacetylates chromatin-associated histone proteins.	HDAC Inhibitor CXD101 | therapeutic_agents	C1909	therapeutic_agents
C	C113792	C177537	GDC Value Terminology	C113792	Dordaviprone	A water soluble, orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) and extracellular signal-regulated kinase (ERK), with potential antineoplastic activity. Upon administration, dordaviprone binds to and inhibits the activity of Akt and ERK, which may result in inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt signal transduction pathway as well as the mitogen-activated protein kinase (MAPK)/ERK-mediated pathway. This may lead to the induction of tumor cell apoptosis mediated by tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)/TRAIL death receptor type 5 (DR5) signaling in AKT/ERK-overexpressing tumor cells. The PI3K/Akt signaling pathway and MAPK/ERK pathway are upregulated in a variety of tumor cell types and play a key role in tumor cell proliferation, differentiation and survival by inhibiting apoptosis. In addition, ONC201 is able to cross the blood-brain barrier.	Akt/ERK Inhibitor ONC201 | therapeutic_agents	C1909	therapeutic_agents
C	C12413	C177537	GDC Value Terminology	C12413	Urinary System	The organs involved in the creation and excretion of urine.	Urinary system, NOS | progression_or_recurrence_anatomic_site || Urinary system, NOS | site_of_resection_or_biopsy || Urinary system, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C177570	site_of_resection_or_biopsy || tissue_or_organ_of_origin || progression_or_recurrence_anatomic_site
C	C150756	C177537	GDC Value Terminology	C150756	Maplirpacept	A soluble recombinant antibody-like fusion protein composed of the N-terminal CD47 binding domain of human signal-regulatory protein alpha (SIRPa; CD172a) linked to an Fc domain derived from human immunoglobulin G subtype 4 (IgG4), with potential immune checkpoint inhibitory, phagocytosis-inducing and antineoplastic activities. Upon administration, maplirpacept selectively targets and binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with endogenous SIRPa, a cell surface protein expressed on macrophages. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation. This induces pro-phagocytic signaling resulting from the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1) expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects tumor cells from phagocytosis, thereby allowing these cells to proliferate and survive.	SIRPa-IgG4-Fc Fusion Protein TTI-622 | therapeutic_agents	C1909	therapeutic_agents
C	C153249	C177537	GDC Value Terminology	C153249	Binary Alignment Map	A binary representation of a sequence alignment map (SAM), a compact and indexable representation of nucleotide sequence alignments, compressed by the BGZF (Blocked GNU Zip Format) library.	BAM | data_format	C42761	data_format
C	C153250	C177537	GDC Value Terminology	C153250	FASTQ Format	A text-based format for storing a biological sequence that encodes the nucleotide calls as well as their quality scores. It is an extension of the FASTA format.	FASTQ | data_format	C42761	data_format
C	C153427	C177537	GDC Value Terminology	C153427	EGFR/HER2 Inhibitor ABT-101	An orally bioavailable dual kinase inhibitor of epidermal growth factor receptor (EGFR; ErbB1) and human epidermal growth factor receptor 2 (HER2; EGFR2; ErbB2), including EGFR L858R, EGFR T790M and HER2 exon 20 insertion (Ex20ins) mutations, with potential antineoplastic activity. Upon oral administration, EGFR/HER2 inhibitor ABT-101 targets, binds to and inhibits the activity of EGFR or HER2 insertions or mutations. This prevents EGFR/HER2-mediated signaling, which may induce cell death and inhibit tumor growth in EGFR/HER2-overexpressing tumor cells. The ErbB receptor tyrosine kinase family is involved in key cellular functions, including cell growth and survival. EGFR and HER2 alterations constitutively upregulate kinase activity.	EGFR Inhibitor DBPR112 | therapeutic_agents	C1909	therapeutic_agents
C	C154549	C177537	GDC Value Terminology	C154549	Lutetium Lu 177-DOTA-EB-TATE	A radioconjugate consisting of Evans blue (EB) modified, tyrosine-containing somatostatin analog, Tyr3-octreotate (TATE), conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecane tetraacetic acid (DOTA), and radiolabeled with the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity. Upon intravenous administration, lutetium Lu 177-DOTA-EB-TATE binds to somatostatin receptors (SSTRs), specifically with high affinity to type 2 SSTRs (SSTR2s), present on the cell membranes of many neuroendocrine tumor (NET) cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR2-positive cells. The incorporation of an albumin-binding moiety through EB modification allows lutetium Lu 177-DOTA-EB-TATE to reversibly bind to endogenous albumin, potentially extending half-life and increasing targeted accumulation of the drug in tumors. SSTRs, especially SSTR2s, are expressed at relatively higher levels in many tumor cell types and tumor blood vessels, compared to normal tissues.	Lutetium Lu 177-DOTA-EB-TATE | therapeutic_agents	C1909	therapeutic_agents
C	C156700	C177537	GDC Value Terminology	C156700	Gumarontinib	An orally bioavailable, small molecule inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon oral administration, gumarontinib targets and binds to the c-Met protein, thereby disrupting c-Met-dependent signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.	Glumetinib | therapeutic_agents	C1909	therapeutic_agents
C	C160714	C177537	GDC Value Terminology	C160714	Lomvastomig	A bispecific antibody directed against both the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, lomvastomig simultaneously targets and binds to both TIM-3 and PD-1 expressed on certain T-cells. This blocks the interaction of TIM-3 with some of its physiologic ligands and prevents the activation of PD-1 by its ligands, programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is often co-expressed with PD-1 on tumor-antigen-specific T-cells. Dual checkpoint blockade of PD-1 and TIM-3 may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.	Anti-PD-1/TIM-3 Bispecific Antibody RO7121661 | therapeutic_agents	C1909	therapeutic_agents
C	C162375	C177537	GDC Value Terminology	C162375	Plogosertib	A competitive inhibitor for adenosine triphosphate (ATP) binding to polo-like kinase 1 (PLK1; PLK-1; STPK13), with potential antineoplastic activity. Upon administration, plogosertib selectively targets, binds to and inhibits PLK1, which disrupts mitosis and induces selective G2/M cell-cycle arrest followed by apoptosis in PLK1-overexpressing tumor cells. PLK1, named after the polo gene of Drosophila melanogaster, is a serine/threonine kinase that is crucial for the regulation of mitosis, and plays a key role in tumor cell proliferation, transformation and invasion. PLK1 expression is upregulated in a variety of tumor cell types and high expression is associated with increased aggressiveness and poor prognosis.	PLK1 Inhibitor CYC140 | therapeutic_agents	C1909	therapeutic_agents
C	C163976	C177537	GDC Value Terminology	C163976	Voxalatamab	An immunoglobulin G4 (IgG4) bispecific antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) human prostate-specific membrane antigen (PSMA), fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, voxalatamab simultaneously binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and PSMA found on PSMA-expressing tumor cells. This activates and redirects CTLs to PSMA-expressing tumor cells, which results in the CTL-mediated cell death of PSMA-expressing tumor cells. PSMA, a tumor associated antigen, is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.	Anti-PSMA/CD3 Bispecific Antibody JNJ-63898081 | therapeutic_agents	C1909	therapeutic_agents
C	C164057	C177537	GDC Value Terminology	C164057	Smoke Exposure	Environmental, occupational or consumer-based exposure to airborne gases and particulates produced when materials undergo combustion or thermal decomposition.	Smoke | exposure_type || Smoke exposure, NOS | type_of_smoke_exposure	C157103 || C164057	exposure_type || type_of_smoke_exposure
C	C167064	C177537	GDC Value Terminology	C167064	Azenosertib	An inhibitor of the tyrosine kinase Wee1 (Wee1-like protein kinase; Wee1A kinase; WEE1hu) with potential antineoplastic sensitizing activity. Although the exact mechanism of action by which this agent inhibits Wee1 has yet to be disclosed, upon administration of ZN-c3, this agent targets and inhibits Wee1. Inhibition of Wee1 promotes both premature mitosis and a prolonged mitotic arrest leading to cell death in susceptible tumor cells, such as p53-deficient or mutated human cancers that lack the G1 checkpoint, upon treatment with DNA-damaging chemotherapeutic agents. Unlike normal cells, most p53-deficient or mutated human cancers lack the G1 checkpoint as p53 is the key regulator of the G1 checkpoint and these cells rely on the G2 checkpoint for DNA repair to damaged cells. Annulment of the G2 checkpoint may therefore make p53-deficient tumor cells more vulnerable to antineoplastic agents and enhance their cytotoxic effect. Overexpression of Wee1 occurs in several cancer types and high expression of Wee1 is associated with poor outcomes. Wee1 phosphorylates Cdc2 in the Cdc2/cyclin B (CDK1/cyclin B) complex which blocks progression from G2 into mitosis; it negatively regulates the G2 checkpoint by disallowing entry into mitosis in response to DNA damage.	Wee1 Inhibitor ZN-c3 | therapeutic_agents	C1909	therapeutic_agents
C	C167188	C177537	GDC Value Terminology	C167188	Davutamig	A bispecific monoclonal antibody that targets two different epitopes of the human tumor-associated antigen (TAA) MET (c-MET; hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon administration, davutamig targets and binds to two different, non-overlapping epitopes on MET expressed on thd tumor cell surface, thereby forming unique davutamig-MET complexes. The binding of davutamig to the MET epitopes and the unique complex formation causes MET internalization and degradation. This prevents MET-mediated signaling and inhibits growth of MET-driven tumor cells. MET, a receptor tyrosine kinase, is overexpressed on the cell surfaces of various solid tumor cell types where it is involved in epithelial-mesenchymal transition; it plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.	MET x MET Bispecific Antibody REGN5093 | therapeutic_agents	C1909	therapeutic_agents
C	C170915	C177537	GDC Value Terminology	C170915	Ispectamab Debotansine	An antibody-drug conjugate (ADC) consisting of ispectamab, a humanized immunoglobulin G1 (IgG1)-kappa monoclonal antibody against the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor (TNF) receptor superfamily, member 17; TNFRSF17) site-specifically conjugated, with a non-cleavable linker, to a maytansinoid payload, with potential antineoplastic activity. Upon administration of ispectamab debotansine, the ispectamab moiety targets and binds to the cell surface antigen BCMA expressed on certain cancer cells. Upon binding and internalization, the maytansinoid payload binds to tubulin, thereby affecting microtubule assembly/disassembly dynamic, and prevents cell division and reduces cell growth of BCMA-expressing cancer cells. BCMA, a receptor for a proliferation-inducing ligand (APRIL; TNF ligand superfamily member 13; TNFSF13), and B-cell activating factor (BAFF), is overexpressed on malignant plasma cells and plays a key role in plasma survival.	Anti-BCMA Antibody-drug Conjugate CC-99712 | therapeutic_agents	C1909	therapeutic_agents
C	C174208	C177537	GDC Value Terminology	C174208	Lirafugratinib	An orally bioavailable inhibitor of the fibroblast growth factor receptor 2 (FGFR2), with potential antineoplastic activity. Upon oral administration, lirafugratinib binds to and inhibits FGFR2, which results in the inhibition of FGFR2-mediated signal transduction pathways. This inhibits the proliferation of FGFR2-overexpressing tumor cells. FGFR2, a receptor tyrosine kinase upregulated in many tumor cell types, plays a key role in cellular proliferation, migration and survival.	FGFR2 Inhibitor RLY-4008 | therapeutic_agents	C1909	therapeutic_agents
C	C175301	C177537	GDC Value Terminology	C175301	Thorium Th 227 Pelgifatamab Corixetan	A radioimmunoconjugate consisting of pelgifatamab, a monoclonal antibody targeting the tumor-associated antigen (TAA) human prostate-specific membrane antigen (PSMA), conjugated to the chelator corixetan, and labeled with the alpha-emitting radioisotope thorium Th 227, with potential antineoplastic activity. Upon administration of thorium Th 227 pelgifatamab corixetan, the pelgifatamab moiety targets and specifically binds to PSMA on tumor cells, thereby delivering a cytotoxic dose of alpha radiation to cells expressing PSMA. PSMA is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.	Thorium Th 227 Anti-PSMA Monoclonal Antibody BAY 2315497 | therapeutic_agents	C1909	therapeutic_agents
C	C175447	C177537	GDC Value Terminology	C175447	Vodudeutentan Sodium	An antagonist of the immune checkpoint endothelin B receptor (ETBR; EDNRB), with potential immunomodulating and antineoplastic activities. Upon administration, the ETBR blocker ENB 003 selectively targets and binds to ETBR expressed on tumor cells. This prevents ETBR-mediated signaling and may abrogate the immunosuppressive tumor microenvironment (TME), may enhance a T-cell mediated anti-tumor immune response and may inhibit proliferation of ETBR-expressing tumor cells. ETBR, a G-protein coupled receptor, is overexpressed in a variety of tumor cell types and plays a key role in tumor cell proliferation, invasion, epithelial-mesenchymal transition (EMT) and angiogenesis. It also plays a role in tumor immunosuppression and blocks T-cell trafficking.	Endothelin B Receptor Blocker ENB 003 | therapeutic_agents	C1909	therapeutic_agents
C	C2639	C177537	GDC Value Terminology	C2639	Taurolidine	A synthetic broad-spectrum antimicrobial with antibacterial, antifungal, anticoagulant, and potential antiangiogenic activities. Taurolidine, derived from the amino acid taurine, binds to and neutralizes bacterial exotoxins and endotoxins, or lipopolysaccharides (LPS). Taurolidine binding to LPS prevents bacterial adherence to host epithelial cells, thereby prevents bacterial invasion of uninfected host cells. Although the mechanism underlying its antineoplastic activity has not been fully elucidated, it may be related to this agent's anti-adherence property. In addition, taurolidine also promotes apoptosis by inducing various apoptotic factors and suppresses the production of vascular endothelial growth factor (VEGF), a protein that plays an important role in angiogenesis.	Taurolidine | therapeutic_agents	C1909	therapeutic_agents
C	C3712	C177537	GDC Value Terminology	C3712	Squamous Papilloma	A benign epithelial neoplasm characterized by a papillary growth pattern and a proliferation of neoplastic squamous cells without morphologic evidence of malignancy. Most frequently it arises in the oral cavity, nasopharynx, larynx, esophagus, vagina, and vulva.	8052/0 | morphology || Keratotoc papilloma | primary_diagnosis || Squamous cell papilloma, NOS | primary_diagnosis || Squamous papilloma | primary_diagnosis || Squamous papilloma; solitary | additional_pathology_findings	C158809 || C176985 || C177621	additional_pathology_findings || morphology || primary_diagnosis
C	C3762	C177537	GDC Value Terminology	C3762	Adenomatoid Tumor	A benign, well-circumscribed neoplasm arising from mesothelial cells. It is characterized by the formation of glandular and tubular patterns. It usually involves the paratesticular region, uterus, and fallopian tube. Rare cases involving the pleura, peritoneum, adrenal gland, and liver have also been reported.	9054/0 | morphology || Adenomatoid tumor, NOS | primary_diagnosis || Epithelioid mesothelioma, benign | primary_diagnosis || Mesothelioma, benign | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C3765	C177537	GDC Value Terminology	C3765	Multicystic Mesothelioma	A mesothelial neoplasm that arises from the peritoneum and rarely the pleura. It is characterized by the presence of multiple cysts lined by flattened or cuboidal mesothelial cells. There is no evidence of significant cytologic atypia or increased mitotic activity. It may reoccur. Rare cases of transformation to malignant mesothelioma have been reported.	9055/0 | morphology || Cystic mesothelioma, NOS | primary_diagnosis || Multicystic mesothelioma, benign | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C3786	C177537	GDC Value Terminology	C3786	Mesothelial Neoplasm	A neoplasm characterized by the proliferation of neoplastic mesothelial cells. It usually arises from the pleura or peritoneum. This category includes malignant mesothelioma, adenomatoid tumor (benign mesothelioma), well differentiated papillary mesothelial tumor, and multicystic mesothelioma.	9050/3 | morphology || Mesothelial Neoplasms | disease_type || Mesothelioma | relationship_primary_diagnosis || Mesothelioma, NOS | primary_diagnosis	C176985 || C177621 || C178243 || C2991	morphology || primary_diagnosis || relationship_primary_diagnosis || disease_type
C	C3801	C177537	GDC Value Terminology	C3801	Hemangioblastoma	A rare, slow-growing tumor of uncertain histogenesis. It affects the central nervous system and infrequently other sites. It is composed of stromal cells and abundant capillaries.	9161/1 | morphology || Angioblastoma | primary_diagnosis || Haemangioblastoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C3842	C177537	GDC Value Terminology	C3842	Urothelial Papilloma	A rare benign neoplasm that arises from the urinary tract and is characterized by the presence of a papillary growth with a central fibrovascular core. The latter is lined by normal urothelium.	8120/1 | morphology || Papilloma of bladder | primary_diagnosis || Urothelial papilloma, NOS | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C39842	C177537	GDC Value Terminology	C39842	Urachal Carcinoma	A rare variant of carcinoma of the urachal remnant of bladder.	Urachal carcinoma | primary_diagnosis	C177621	primary_diagnosis
C	C39954	C177537	GDC Value Terminology	C39954	Brenner Tumor	A tumor composed of solid and cystic nests of neoplastic urothelial-type cells in an abundant stromal component that is dense and fibroblastic in nature. It arises from the ovary and very rarely the paratesticular structures. It includes benign Brenner tumor, borderline Brenner tumor, and malignant Brenner tumor.	9000/0 | morphology || Brenner tumor, NOS | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C4030	C177537	GDC Value Terminology	C4030	Urothelial Carcinoma	A carcinoma arising from the urothelial lining of the urinary tract (bladder, renal pelvis, ureter, or urethra).	8120/3 | morphology || Urothelial carcinoma, NOS | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C40345	C177537	GDC Value Terminology	C40345	Testicular Germ Cell Neoplasia In Situ	A non-invasive lesion of the testis, characterized by the presence of malignant large germ cells with abundant cytoplasm in the seminiferous tubules. It may be associated with undescended or atrophic testis and infertility. The vast majority of cases progress to invasive germ cell tumors.	9064/2 | morphology || Intratubular malignant germ cells | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C4068	C177537	GDC Value Terminology	C4068	Trabecular Adenocarcinoma	An adenocarcinoma characterized by the presence of a trabecular glandular architectural pattern.	8190/3 | morphology || Trabecular adenocarcinoma | primary_diagnosis || Trabecular carcinoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C4092	C177537	GDC Value Terminology	C4092	Benign Epithelial Neoplasm	A neoplasm that arises from epithelial cells and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.	8010/0 | morphology || 8011/0 | morphology || Epithelial tumor, benign | primary_diagnosis || Epithelioma, benign | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C4264	C177537	GDC Value Terminology	C4264	Clear Cell Sarcoma of the Kidney	A rare pediatric sarcoma affecting the kidney. It is characterized by the presence of epithelioid or spindle cells forming cords or nests, separated by fibrovascular septa. It metastasizes to lung, bone, brain and soft tissue.	8964/3 | morphology || Clear cell sarcoma of kidney | primary_diagnosis || Clear cell sarcoma of the kidney (CCSK) | tumor_code	C176985 || C177615 || C177621	morphology || tumor_code || primary_diagnosis
C	C4270	C177537	GDC Value Terminology	C4270	Malignant Ovarian Brenner Tumor	A malignant neoplasm that arises from the ovary. It is characterized by the presence of an invasive malignant urothelial-type cellular component and nests of benign urothelial-type cells in a fibrotic stroma. When the neoplasm is confined to the ovary, the prognosis is good.	9000/3 | morphology || Brenner tumor, malignant | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C4456	C177537	GDC Value Terminology	C4456	Malignant Mesothelioma	A malignant neoplasm that arises from mesothelial cells, usually in the pleura or peritoneum. It is associated with exposure to asbestos.	9050/3 | morphology || Mesothelioma, malignant | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C47845	C177537	GDC Value Terminology	C47845	FASTA Format	A text-based format for representing either nucleotide sequences or peptide sequences. It consists of a single-line description, followed by lines of sequence data.  Sequences are represented in the standard IUPAC-IUB (International Union of Pure and Applied Chemistry-International Union of Biochemistry Commission on Biochemical Nomenclature) single letter amino acid and nucleic acid base codes. It is an extension of the FAST-P (protein) and FAST-N (nucleotide) alignment tools.	FASTA | data_format	C42761	data_format
C	C5530	C177537	GDC Value Terminology	C5530	Prostate Acinar Sarcomatoid Carcinoma	A rare acinar adenocarcinoma of the prostate gland with unfavorable prognosis. It is composed of both malignant glandular and sarcomatous components. The sarcomatous component contains a malignant spindle cell proliferation or specific mesenchymal elements including osteosarcoma, chondrosarcoma, and leiomyosarcoma.	Acinar adenocarcinoma, sarcomatoid | primary_diagnosis	C177621	primary_diagnosis
C	C5950	C177537	GDC Value Terminology	C5950	Basal Cell Adenoma	A salivary gland benign epithelial neoplasm with a uniform, monomorphic appearance that is dominated by basal cells forming trabecular structures. It is rare and occurs mostly on the parotid gland. The average age of patients has been reported to be 58 years. Swelling is the most constant clinical finding.	8147/0 | morphology || Basal cell adenoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C65165	C177537	GDC Value Terminology	C65165	Inverted Squamous Papilloma	A benign epithelial neoplasm characterized by an endophytic growth, papillary pattern, and proliferation of neoplastic squamous cells without morphologic evidence of malignancy.	8053/0 | morphology || Squamous cell papilloma, inverted | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C6536	C177537	GDC Value Terminology	C6536	Peritoneal Multicystic Mesothelioma	A mesothelial neoplasm that arises from the peritoneum and usually affects young to middle aged females. Grossly, it presents as a large multiloculated tumor mass, usually in the pelvic peritoneum. Histologically it is characterized by the presence of multiple cysts that are lined by one or more layers of mesothelial cells that do not show atypia. Patients usually present with abdominal or pelvic mass and pain. The clinical course is indolent. The tumor may reoccur, but transformation to malignant mesothelioma is rare.	9055/0 | morphology	C176985	morphology
C	C6569	C177537	GDC Value Terminology	C6569	Congenital Mesoblastic Nephroma	A low grade childhood congenital malignant neoplasm arising from the kidney. It is characterized by the presence of fibroblastic cells. The majority of cases occur in the first year of life. Complete excision is usually associated with an excellent prognosis.	8960/1 | morphology || Mesoblastic nephroma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C66748	C177537	GDC Value Terminology	C66748	Testicular Sex Cord-Stromal Tumor, Not Otherwise Specified	A sex cord-stromal tumor of the testis in which the neoplastic cells do not show specific differentiation.	8591/1 | morphology || Sex cord-gonadal stromal tumor, incompletely differentiated | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C66991	C177537	GDC Value Terminology	C66991	Testicular Mixed Sex Cord-Stromal Tumor	A sex cord-stromal tumor of the testis which may contain any combination of cell types, for example Sertoli cells, Leydig cells, and granulosa cells. Symptoms include testicular swelling and gynecomastia.	8592/1 | morphology || Sex cord-gonadal stromal tumor, mixed forms | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C71687	C177537	GDC Value Terminology	C71687	Unchanged	The status is unaltered or similar to the previous state.	DU-Disease Unchanged | best_overall_response || DU-Disease Unchanged | disease_response	C50995 || C94536	disease_response || best_overall_response
C	C7438	C177537	GDC Value Terminology	C7438	Invasive Papillary Adenocarcinoma	A carcinoma that has papillary growth and invades the wall and/or the surrounding tissues of the organ it originates from.	8503/3 | morphology || Infiltrating and papillary adenocarcinoma | primary_diagnosis || Infiltrating papillary adenocarcinoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C78198	C177537	GDC Value Terminology	C78198	Calaspargase Pegol	An intravenous formulation containing E.coli-derived L-asparaginase II conjugated with succinimidyl carbonate monomethoxypolyethylene glycol (SC-PEG), with potential antineoplastic activity. Upon administration of calaspargase pegol, L-asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting cells of asparagine; asparagine depletion blocks protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle and ultimately induces tumor cell death. Asparagine is critical to protein synthesis in acute lymphoblastic leukemia (ALL) cells which, unlike normal cells, cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. Pegylation decreases enzyme antigenicity and increases its half life. SC is used as a PEG linker to facilitate attachment to asparaginase and enhances the stability of the formulation.	Calaspargase Pegol-mknl | therapeutic_agents	C1909	therapeutic_agents
C	C82937	C177537	GDC Value Terminology	C82937	MAGE-TAB	A tab-delimited, spreadsheet-based format that can be used for annotating and communicating microarray data with experimental details in a MIAME (Minimum Information About a Microarray Experiment) compliant fashion.	MAGE-TAB | data_format || MAGETAB | data_format	C42761	data_format
C	C9063	C177537	GDC Value Terminology	C9063	Malignant Testicular Germ Cell Tumor	A malignant germ cell tumor that arises from the testis. It predominantly affects young men. Seminoma is the most frequently seen malignant testicular germ cell tumor, followed by embryonal carcinoma and yolk sac tumor.	Testicular Cancer | relationship_primary_diagnosis	C178243	relationship_primary_diagnosis
C	C9385	C177537	GDC Value Terminology	C9385	Renal Cell Carcinoma	A carcinoma arising from the renal parenchyma.  There is a strong correlation between cigarette smoking and the development of renal cell carcinoma.  The clinical presentation includes : hematuria, flank pain and a palpable lumbar mass.  A high percentage of renal cell carcinomas are diagnosed when an ultrasound is performed for other purposes.  Radical nephrectomy is the standard intervention procedure.  Renal cell carcinoma is generally considered to be resistant to radiation treatment and chemotherapy.	Renal cell adenocarcinoma | primary_diagnosis	C177621	primary_diagnosis
C	C9459	C177537	GDC Value Terminology	C9459	Borderline Ovarian Brenner Tumor	A neoplasm of low malignant potential arising from the ovary. It is characterized by the presence of neoplastic atypical urothelial-type cells in a fibrotic stroma without evidence of invasion.	9000/1 | morphology || Brenner tumor, borderline malignancy | primary_diagnosis || Brenner tumor, proliferating | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis